Welcome to our dedicated page for Genworth Finl SEC filings (Ticker: GNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scanning 300-plus pages to locate Genworth Financial’s long-term care reserve roll-forward or Enact’s latest risk-to-capital ratio can feel overwhelming. Actuarial tables, mortgage insurance delinquency data and nuanced capital disclosures are scattered across multiple SEC documents, making it hard to act before the market digests the details.
Stock Titan removes that friction. Our AI reads every Genworth Financial annual report 10-K simplified, each Genworth Financial quarterly earnings report 10-Q filing and all Genworth Financial 8-K material events explained the moment they hit EDGAR. You’ll see concise summaries of LTCI reserve changes, statutory capital movements and debt-reduction plans—plus plain-English answers to questions such as “understanding Genworth Financial SEC documents with AI” or “where to find Genworth Financial proxy statement executive compensation.”
Complete coverage with real-time intelligence:
- Instant alerts on Genworth Financial insider trading Form 4 transactions and Genworth Financial Form 4 insider transactions real-time
- AI-highlighted trends in delinquency rates and claim reserves drawn from 10-Qs—ideal for quick Genworth Financial earnings report filing analysis
- Clickable call-outs to executive pay metrics straight from the proxy
Analysts use these insights to monitor executive stock sales before earnings, gauge capital available for buybacks, and benchmark reserve adequacy across cycles. Stop mining PDFs: get the data that drives decisions in minutes, not hours.
Genworth Financial Inc. reported an insider stock transaction by its President and CEO, who is also a director. On December 2, 2025, the reporting person sold 40,000 shares of Genworth common stock at a price of $8.64 per share. After this sale, the reporting person beneficially owned 5,107,444 shares directly and 89,456 shares indirectly through trusts for the benefit of his children.
The filing notes that earlier in the year, on May 30, 2025, a grantor retained annuity trust (GRAT) terminated, resulting in 419,534 shares moving into the reporting person’s direct ownership and 89,456 shares being transferred to children’s trusts. The form also allows for the indication that the transaction may have been made under a pre-arranged Rule 10b5-1 trading plan.
Genworth Financial (GNW) insider plans Rule 144 sale after stock vesting. A holder has filed to sell 40,000 shares of GNW common stock through Fidelity Brokerage Services on the NYSE, with an indicated aggregate market value of $345,600. The filing shows that these shares were acquired on 03/03/2025 via restricted stock vesting from the issuer as compensation. As of the filing, 399,380,567 shares of GNW common stock were outstanding, providing context for the size of the planned sale.
Genworth Financial (GNW) executive David F. Kurzawa, EVP and General Counsel, reported a stock sale in a Form 4 filing. On 11/24/2025, he sold 40,000 shares of Genworth common stock at a weighted average price of $8.5101 per share through a series of broker-assisted transactions within a price range of $8.51 to $8.54 per share.
After this transaction, he beneficially owned 302,000 shares of Genworth common stock directly, plus 4,746.438 shares held indirectly through a 401(k) plan. The filing notes that detailed trade breakdowns within the reported price range are available upon request from the reporting person.
Genworth Financial (GNW) filed a Form 4 reporting that its EVP and Chief HR Officer made a charitable gift of company stock. On 11/10/2025, the insider transferred 3,513 shares of Common Stock, coded “G” for gift, at a reported price of $0.
After this transaction, the insider beneficially owns 133,571 shares, listed as direct ownership. The footnote states the shares were gifted to a charitable organization.
Genworth Financial (GNW) received a Schedule 13G from Donald Smith & Co., Inc. and DSCO Value Fund, L.P. reporting beneficial ownership of 24,976,084 shares of GNW common stock, equal to 6.09% of the class, tied to an event date of September 30, 2025.
The filers certify the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. Donald Smith & Co., Inc. files as an investment adviser, with economic rights to dividends and sale proceeds residing with its clients. To its knowledge, no single client holds more than 5% of Genworth’s outstanding common stock.
Genworth Financial, Inc. (GNW) furnished its quarterly materials. The company provided a press release and a financial supplement covering results for the quarter ended September 30, 2025, as Exhibits 99.1 and 99.2.
The information was furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated by reference into other filings unless expressly stated.
Genworth Financial insider transaction: Rohit Gupta, identified as an officer (President & CEO, Enact) of Genworth Financial, sold 86,406 shares of Genworth common stock on 08/27/2025 at a weighted average sales price of $8.6784 per share. After the sale, Mr. Gupta directly beneficially owned 794,630 shares. In addition, 7,054.809 shares are reported as indirectly owned via a 401(k) plan. The Form 4 was signed by a power of attorney on 08/29/2025. The filer discloses the sale price range ($8.67 to $8.69) and offers to provide a detailed allocation of shares sold at each price on request.
Genworth Financial (GNW) filed an amended Rule 144 notice reporting a proposed sale of 86,406 common shares through J.P. Morgan Securities LLC, with an aggregate market value of $749,140. The shares represent part of the filer’s compensation: 59,080 shares were acquired on 03/25/2024 and 27,326 shares on 03/01/2024. The filing lists the approximate sale date as 08/27/2025 and reports 410,433,925 shares outstanding. The filer certifies no undisclosed material adverse information and provides standard Rule 144 representations.